Sollazzo D
Electroencephalogr Clin Neurophysiol. 1985 Oct;61(4):236-42. doi: 10.1016/0013-4694(85)91089-2.
Data obtained from a total of 246 monocular VEPs performed on 46 patients, 35 with Parkinson's disease and 11 with arteriosclerotic parkinsonism, classed in the first 3 stages on the Hohen and Yahr disability scale, are reported. Our data show a delay of mean P100 latency in the primary parkinsonian group during the period of washout from L-DOPA therapy as well as in the secondary parkinsonian group. But the interocular mean difference in VEP P100 results significantly increased in primary parkinsonism only. A more important different behaviour between primary and secondary parkinsonism concerns a possible reduction of VEP delay related to L-DOPA/carbidopa treatment. An improvement of P100 delay can be noticed after acute and after chronic DOPA therapy in primary parkinsonism only. The above data confirm previous reports concerning VEP delays in Parkinson's disease, suggesting monitoring of different pharmacological sensitivity in idiopathic and arteriosclerotic parkinsonian patients as a useful method.
报告了对46例患者进行的总共246次单眼视觉诱发电位（VEP）检查所获得的数据，其中35例为帕金森病患者，11例为动脉硬化性帕金森综合征患者，这些患者根据霍恩和雅尔残疾量表被分类在前3个阶段。我们的数据显示，在左旋多巴治疗的洗脱期，原发性帕金森病组以及继发性帕金森病组的平均P100潜伏期均延迟。但是，仅在原发性帕金森病中，VEP P100结果的眼间平均差异显著增加。原发性和继发性帕金森病之间更重要的不同表现涉及与左旋多巴/卡比多巴治疗相关的VEP延迟可能减少。仅在原发性帕金森病中，急性和慢性多巴治疗后可观察到P100延迟有所改善。上述数据证实了先前有关帕金森病中VEP延迟的报道，表明监测特发性和动脉硬化性帕金森病患者的不同药理敏感性是一种有用的方法。
